CDMO Outsourcing Market Size, Share, Trends, Growth and Forecast 2026–2034

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Overview Analysis By Fortune Business Insights

Market Size & Growth Outlook

According to Fortune Business Insights: The global Contract Development and Manufacturing Organization (CDMO) outsourcing market was valued at USD 130.80 billion in 2018 and is projected to reach USD 278.98 billion by 2026, exhibiting a CAGR of 10.0% during the forecast period (2019–2026). North America was the leading regional market, valued at USD 48.70 billion in 2018, driven by its established CDMO ecosystem and extensive pharmaceutical industry collaborations.

CDMOs deliver an integrated suite of services spanning the full pharmaceutical value chain — from drug discovery and preclinical research through clinical trials, active pharmaceutical ingredient (API) manufacturing, finished product development, and commercial-scale production. These organizations bridge critical capability gaps for pharmaceutical and biotech companies, enabling faster regulatory approvals, reduced development timelines, and more cost-effective drug commercialization. The growing complexity of novel therapies, increasing biologics pipelines, and limited in-house manufacturing capabilities at many small and emerging pharmaceutical companies are central drivers of CDMO outsourcing demand globally.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102502

Market Trends

Rapid Consolidation Through Mergers & Acquisitions: The CDMO market is undergoing rapid consolidation as organizations seek to expand their service portfolios, geographic reach, and technological capabilities. CDMOs are increasingly merging with small and large pharmaceutical, biotechnology, and life science companies to strengthen their end-to-end drug development and manufacturing offerings while reducing overall operational costs. In October 2018, Recipharm AB acquired Sanofi's inhalation contract manufacturing business to expand its respiratory product development capabilities. In January 2019, Cambrex Corporation completed the acquisition of Avista Pharma Solutions to strengthen its small molecule CDMO services, while Catalent completed the acquisition of Paragon Biosciences in May 2019 to deepen its gene therapy manufacturing capabilities. These consolidation activities are enabling CDMOs to offer broader one-stop-shop solutions that pharmaceutical clients increasingly prefer for accelerating drug development.

Market Drivers

Growing Demand for Pharmaceutical Products: The rising global burden of chronic diseases — driven by population growth, aging demographics, urbanization, and westernized lifestyle adoption — is compelling pharmaceutical companies to accelerate the development and commercialization of effective therapies. According to the World Health Organization, the proportion of non-communicable disease (NCD) burden was projected to reach 57% in 2020, reinforcing sustained demand for innovative drug products. CDMOs play a pivotal role in simplifying the pharmaceutical supply chain, providing fully integrated services from development to commercial manufacturing and enabling faster market entry for new therapies.

Biologics and Pipeline Expansion: The growing therapeutic applications of biologics, biosimilars, and gene therapies — alongside an increasing share of complex pipeline molecules — are expanding the scope and value of CDMO services. Small and mid-sized biotech companies developing novel biological therapies increasingly rely on CDMOs to access state-of-the-art R&D infrastructure, regulatory expertise, and manufacturing capabilities they cannot build in-house. The rising availability of integrated CDMO platforms offering advanced technology solutions is further accelerating regulatory approvals and improving drug development efficiency.

Rising Capital Investments and Strategic Collaborations: Growing capital investments from CDMOs in advanced manufacturing facilities, new technology platforms, and geographic expansion are enhancing service capability and supporting market growth. In October 2017, CordenPharma International announced a strategic investment of €3.7 million in its small molecule API manufacturing site in Switzerland, reflecting the sustained commitment of leading CDMOs to infrastructure development. Increasing strategic collaborations between pharmaceutical companies and CDMOs to outsource manufacturing activities are enabling pharmaceutical clients to focus their resources on core research competencies while benefiting from CDMO operational excellence.

Market Restraints

The primary restraint is the presence of stringent government regulations and tightening approval processes for small molecules and biologics in developed markets. Regulatory complexity increases the burden on CDMOs and their clients, potentially extending development timelines and increasing compliance costs. Additionally, small-scale CDMOs lacking state-of-the-art equipment face increased risk of process errors, quality challenges, and pricing pressures — limiting their ability to compete for high-value contracts and constraining market consolidation at the lower end.

Segmentation Analysis

By Service — CMO Segment: The Contract Manufacturing Organization (CMO) segment holds the largest market share. Within CMO services, API manufacturing accounts for the highest revenue share, supported by the growing number of biologics APIs in clinical pipelines and the expanding adoption of API biologics across diverse therapeutic areas. The finished product manufacturing segment — encompassing solid dosage forms, injectables, and specialty formulations — holds the second-largest CMO share. The injectables sub-segment is expected to grow most significantly, driven by rising demand for prefilled syringes, auto-injectors, and other injectable delivery systems for biologics and biosimilars administration. The packaging segment is expected to register moderate growth, supported by patient-centric packaging innovation and dose-monitoring solutions improving medication adherence. Implementation of innovative packaging technologies by pharmaceutical CDMOs is becoming a critical differentiator in commercial manufacturing partnerships.

By Service — CRO Segment: The Contract Research Organization (CRO) segment is segmented into discovery, preclinical, clinical trial, and laboratory services. Clinical trial services dominate the CRO segment throughout the forecast period, driven by rising demand for effective therapies, increasing numbers of products under development, growing R&D investments by pharmaceutical companies, and expanding outsourcing of clinical programs to specialist research partners. Discovery and preclinical services are growing steadily, supported by increasing early-stage pipeline activity and demand for integrated drug discovery platforms that can bridge early research to clinical development.

Regional Outlook

North America leads the global CDMO market, valued at USD 48.70 billion in 2018. The region's dominance reflects the presence of well-established CDMOs, deep pharmaceutical industry partnerships, strong R&D infrastructure, and a robust regulatory framework that supports outsourcing of both manufacturing and clinical research activities. The U.S. remains the single largest country market, benefiting from a large pharmaceutical and biotech sector, significant biologics pipeline activity, and a culture of strategic outsourcing across the drug development value chain. Canada also contributes to regional demand through growing biotech activity and expanding life sciences manufacturing.

Asia Pacific is projected to register the highest CAGR during the forecast period, driven by a combination of cost advantages in R&D and manufacturing, a highly skilled scientific workforce, expanding pharmaceutical manufacturing capacity, and growing domestic pharmaceutical market demand. China, India, Japan, and Australia are the primary contributors, with China and India attracting increasing API manufacturing outsourcing from global pharmaceutical companies seeking cost-effective, large-scale production. The region's growing ability to offer end-to-end CDMO services — including clinical research, API synthesis, formulation development, and commercial manufacturing — is strengthening its competitive position as a global pharmaceutical outsourcing hub.

Europe represents a mature and well-established CDMO market, driven by major pharmaceutical company presence, strong regulatory alignment with the EU framework, and significant biologics and specialty drug manufacturing activity across the U.K., Germany, France, Italy, Spain, and Scandinavia. European CDMOs are increasingly differentiating through advanced biologic manufacturing capabilities, specialized injectables production, and integrated drug development services.

Rest of the World markets are developing, with growth supported by expanding pharmaceutical industries, increasing healthcare investments, and growing domestic drug production capabilities.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/102502

Competitive Landscape

The global CDMO market is fragmented and highly competitive, with leading players including Catalent Inc. (U.S.), Baxter International (U.S.), Vetter Pharma (Germany), Recipharm AB (Sweden), Albany Molecular Research Inc./AMRI (U.S.), Thermo Fisher Scientific Inc./Patheon (U.S.), Unither Pharmaceuticals (France), DPT Laboratories Ltd. (U.S.), and NextPharma Technologies. Competition centers on service breadth across the drug development continuum, geographic reach, manufacturing technology sophistication, regulatory track record, and biologics capabilities. Strategic mergers and acquisitions remain the primary mechanism through which leading CDMOs are expanding service offerings, entering new geographic markets, and building fully integrated development-to-commercialization platforms that pharmaceutical clients increasingly prefer.